drugset
drugset / Trial / NCT05844462

Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

NCT05844462 ↗

Phase 3 Recruiting 200 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupTriple-blindTreatment

Summary

ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups. Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.

Timeline

Start
2024-02-01
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 20 mg Oral
Subject Tadalafil Small molecule 40 mg Oral

Indications

chronic obstructive pulmonary disease pulmonary hypertension